2005 issue 4


Volume 14, issue 4

Original article

Influence of apolipoprotein E, low-density lipoprotein (LDL) receptor related protein (LRP) and interleukin 1 ß polymorphisms and of plasma lipids level on dementia treatment

Hanna Wehr1, Wanda Łojkowska2, Małgorzata Bednarska-Makaruk1, Anna Bochyńska2, Ałła Graban2, DOROTA HOFMANN-ZACHARSKA3, Maria Rodo1, Danuta Ryglewicz2
1. Department of Genetics, Institute of Psychiatry and Neurology, Warsaw, Poland
2. Department of Neurology I, Institute of Psychiatry and Neurology, Warsaw, Poland
3. Clinic of Neurology, Epileptology and Sleep Disorders, Institute of Mother and Child, Warsaw, Poland
Postępy Psychiatrii i Neurologii 2005; 14 (4): 325-329
Keywords: dementia treatment, apolipoprotein E, LDL receptor related protein, interleukin 1ß, cholesterol


Aim. The aim of the work was to study a possible influence of several genes polymorphism and of lipids on the effectiveness of one year dementia treatment with cholinesterase inhibitors.

Methods. The group consisted of 68 patients - 48 with Alzheimer's disease and 20 with mixed dementia. Apolipoprotein E alleles, two polymorphisms of LRP and two of interleukin 1ß genes were identified by DNA analysis. Lipid levels were determined in plasma using enzymatic methods.

Results. No one apolipoprotein E carrier was in the group of bad responders to treatment. A higher frequency of e4 allele carriers showed bad response to treatment as compared with e2 allele carriers. A higher frequency of carriers of the longer 92 allele of [TTTC]n LRP polymorphism and of carriers of T allele of the C766T LRP polymorphism and ofpersons with plasma LDL cholesterol level >135 mg/dl was observed in the group of bad responders comparing with their frequency in the good responders group. The more of those disadvantageous factors had an individual the significantly worse were his treatment results. It was concluded that APOE and LRP polymorphism as well as LDL cholesterol levels could have an influence on the effectiveness of treatment with acetylcholinesterase inhibitors in patients with dementia. The effect was stronger in Alzheimer's disease patients than in patients with mixed dementia.

Conclusions. Our results showed that APOE and LRP polymorphism as well as LDL cholesterol levels could modify the effectiveness of treating patients with dementia with acetylcholinesterase inhibitors.

Address for correspondence:
Prof. Hanna Wehr, Zakład Genetyki Instytutu Psychiatrii i Neurologii, ul. Sobieskiego 9, 02-957 Warszawa, tel. (22) 4582699, fax: (22) 8589169, e-mail: wehr@ipin.edu.pl